Olema Oncology, Inc. (OLMA) shareholders
Close on Nov 17, 2026Market cap $631.73MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (13.80%) | 12,075,062 | 13.80% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (12.50%) | 9,998,060 | 12.50% | 13G (passive) amendment | Feb 27, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.80%), Lampert Mark N (9.80%) and 3 more | 8,939,731 | 9.80% | 13D (active) amendment | Oct 14, 2026 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 7,473,238 | 8.15% | 13G (passive) amendment | Mar 31, 2026 |
| Senai Asefaw, M.D. Joint filing with Paradigm BioCapital Advisors LP (9.99%), Paradigm BioCapital Advisors GP LLC (9.99%) and 1 more | 7,429,355 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Janus Henderson Group PLC | 7,108,488 | 8.20% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 6,244,212 | 7.10% | 13G (passive) amendment | Jun 30, 2026 |
| Raymond Debbane | 4,461,949 | 5.10% | 13G (passive) | Mar 16, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (5.04%), Deep Track Biotechnology Master Fund, Ltd. (5.04%) | 3,442,833 | 5.04% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OLMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,143,062 | 13.88% | $151.91M | +1,756,217 | 0.01% |
| Paradigm Biocapital Advisors LP | 8,670,576 | 9.91% | $108.47M | +650,000 | 2.03% |
| Jupiter Topco LLC | 7,094,413 | 8.11% | $88.80M | New | 0.04% |
| Bain Capital Life Sciences Investors, LLC | 7,085,249 | 8.10% | $88.64M | −387,989 | 5.27% |
| BlackRock, Inc. | 6,714,691 | 7.67% | $84.00M | +1,062,556 | 0.00% |
| Bvf Inc/Il | 5,295,893 | 6.05% | $66.25M | – | 1.69% |
| Siren, L.L.C. | 4,856,949 | 5.55% | $60.76M | +100,000 | 1.23% |
| State Street Corp | 4,316,058 | 4.93% | $53.99M | +378,227 | 0.00% |
| Vanguard Capital Management LLC | 3,341,217 | 3.82% | $41.80M | +257,700 | 0.00% |
| Logos Global Management LP | 3,208,875 | 3.67% | $40.14M | – | 1.73% |
| Franklin Resources Inc | 2,349,586 | 2.69% | $29.39M | +1,130,629 | 0.01% |
| Cormorant Asset Management, LP | 2,150,000 | 2.46% | $26.90M | −1,750,000 | 1.38% |
| Morgan Stanley | 1,832,269 | 2.09% | $22.92M | +616,579 | 0.00% |
| Geode Capital Management, LLC | 1,819,029 | 2.08% | $22.76M | +274,612 | 0.00% |
| Vanguard Portfolio Management LLC | 1,663,218 | 1.90% | $20.81M | +1,070,187 | 0.00% |
| Goldman Sachs Group Inc | 1,567,979 | 1.79% | $19.62M | +522,390 | 0.00% |
| Deep Track Capital, LP | 1,500,000 | 1.71% | $18.77M | New | 0.27% |
| Dimensional Fund Advisors LP | 1,416,533 | 1.62% | $17.72M | +334,099 | 0.00% |
| Lightspeed Management Company, L.L.C. | 1,355,299 | 1.55% | $16.95M | – | 0.71% |
| Kingdon Capital Management, L.L.C. | 1,200,000 | 1.37% | $15.01M | +345,000 | 1.54% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 185 | 102M | 100.0% | 26 / 74 | 60 / 33 | 22M | 15M |
| Q1 2026 | 195 | 101M | 100.0% | 46 / 73 | 51 / 50 | 26M | 11M |
| Q4 2025 | 200 | 91M | 100.0% | 87 / 55 | 39 / 13 | 37M | 14M |
| Q3 2025 | 127 | 68M | 78.1% | 21 / 41 | 37 / 15 | 6M | 8M |
| Q2 2025 | 122 | 71M | 80.7% | 18 / 56 | 28 / 29 | 11M | 6M |
| Q1 2025 | 133 | 66M | 75.3% | 25 / 48 | 42 / 47 | 7M | 13M |
| Q4 2024 | 156 | 71M | 81.5% | 37 / 53 | 39 / 9 | 21M | 8M |
| Q3 2024 | 130 | 59M | 67.2% | 19 / 47 | 43 / 17 | 11M | 10M |
| Q2 2024 | 129 | 61M | 69.9% | 29 / 53 | 33 / 25 | 13M | 9M |
| Q1 2024 | 126 | 57M | 65.3% | 30 / 40 | 35 / 17 | 11M | 6M |
| Q4 2023 | 113 | 52M | 59.9% | 33 / 43 | 21 / 17 | 10M | 5M |
| Q3 2023 | 97 | 47M | 54.1% | 18 / 35 | 31 / 8 | 14M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
208 funds held OLMA in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OLMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,716,953 | 3.11% | $33.99M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,611,290 | 2.98% | $32.67M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,046,399 | 2.34% | $25.60M | 0.03% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,500,000 | 1.71% | $19.79M | 0.34% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,127,200 | 1.29% | $14.87M | 0.01% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 906,900 | 1.04% | $10.38M | 0.14% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 856,422 | 0.98% | $9.81M | 0.03% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 820,000 | 0.94% | $9.39M | 0.30% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 777,200 | 0.89% | $8.90M | 0.40% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 693,867 | 0.79% | $7.94M | 0.32% | Jul 31, 2026 |
| PGIM Jennison Health Sciences Fund | 662,745 | 0.76% | $8.74M | 0.63% | May 29, 2026 |
| Janus Henderson Global Life Sciences Fund | 658,168 | 0.75% | $8.23M | 0.14% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 652,249 | 0.75% | $8.16M | 0.01% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 628,100 | 0.72% | $8.28M | 0.16% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 612,702 | 0.70% | $7.66M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean Bohen | PRESIDENT AND CEO, Director | 237,650 | 0.27% | Feb 4, 2026 |
| Jason O'Byrne | CHIEF FINANCIAL OFFICER | – | – | Sep 2, 2026 |
| Shawnte Mitchell | CHIEF LEGAL OFFICER | 233 | 0.00% | Mar 5, 2026 |
| Sasha Lu Austin | VP of Finance and Controller | 4,488 | 0.01% | Feb 17, 2026 |
| Naseem Zojwalla | CHIEF MEDICAL OFFICER | 103,997 | 0.12% | Feb 4, 2026 |
| David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | 687,607 | 0.79% | Feb 4, 2026 |
| Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | 139,727 | 0.16% | Jan 15, 2026 |
| Cyrus Harmon | Director | 819,798 | 0.94% | Jul 27, 2026 |
| Prakash Raman | Director | – | – | Jun 23, 2026 |
| Value Fund L. P. Biotechnology | Director | 2,906,659 | 3.32% | Jun 23, 2026 |
| Partners OS Ltd. BVF | Director | 447,526 | 0.51% | Jun 23, 2026 |
| Ii Gp Llc Bvf | Director | 623,707 | 0.71% | Jun 23, 2026 |
| Value Trading Fund OS LP Biotechnology | Director | 3,684,068 | 4.21% | Jun 23, 2026 |
| Ian T. Clark | Director | 0 | – | Jun 23, 2026 |
| Cynthia M. Butitta | Director | 83,876 | 0.10% | Jun 23, 2026 |
| Andrew Rappaport | Director | 385,965 | 0.44% | Jun 23, 2026 |
| J. Scott Garland | Director | – | – | Jun 23, 2026 |
| Mark N. Lampert | Director | 2,103,522 | 2.40% | Jun 23, 2026 |
| I. Gp Llc Bvf | Director | – | – | Jun 23, 2026 |
| Inc/Il Bvf | Director | 2,103,522 | 2.40% | Jun 23, 2026 |
| Yi Larson | Director | – | – | Jun 23, 2026 |
| Gp Holdings Llc Bvf | Director | – | – | Jun 23, 2026 |
| Partners L. P/Il Bvf | Director | – | – | Jun 23, 2026 |
| Value Fund Ii Lp Biotechnology | Director | 2,523,265 | 2.88% | Jun 23, 2026 |
| Sandra Horning | Director | – | – | Jun 23, 2026 |
| G. Walmsley Graham | Director | 1,800,000 | 2.06% | Jun 23, 2026 |
| Gorjan Hrustanovic | Director | – | – | Jun 23, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | 7,500,000 | 8.57% | Jan 13, 2025 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 10% owner | – | – | Jan 13, 2025 |
| Bain Capital Life Sciences Fund IV, L.P. | 10% owner | – | – | Jan 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cyrus Harmon Director | Jul 24, 2026 | Sale | −12,500 | $11.71 | $146.38K | 702,770 |
| Cyrus Harmon Director | Jul 23, 2026 | Sale | −12,500 | $11.58 | $144.75K | 715,270 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 4, 2026 | Sale | −24,767 | $24.25 | $600.60K | 233 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 4, 2026 | Option exercise | +25,000 | $4.37 | $109.25K | 25,000 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 4, 2026 | Sale | −233 | $24.69 | $5.75K | 0 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 3, 2026 | Option exercise | +15,000 | $4.37 | $65.55K | 15,000 |
| Shawnte Mitchell CHIEF LEGAL OFFICER | Mar 3, 2026 | Sale | −15,000 | $23.01 | $345.15K | 0 |
| Sasha Lu Austin VP of Finance and Controller | Feb 2, 2026 | Award | +11,700 | – | – | 16,188 |
| Cyrus Harmon Director | Jan 20, 2026 | Sale | −10,000 | $26.88 | $268.80K | 727,770 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Jan 15, 2026 | Sale | −100,000 | $28.73 | $2.87M | 139,727 |
| Cyrus Harmon Director | Jan 14, 2026 | Sale | −3,489 | $29.12 | $101.60K | 737,770 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Sale | −35,003 | $28.99 | $1.01M | 542,761 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Sale | −14,997 | $28.60 | $428.91K | 577,764 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Option exercise | +50,000 | $4.87 | $243.50K | 592,761 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Jan 13, 2026 | Sale | −3,822 | $28.01 | $107.05K | 239,727 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Sale | −200 | $28.49 | $5.70K | 542,761 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Sale | −49,800 | $27.60 | $1.37M | 542,961 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Option exercise | +50,000 | $4.87 | $243.50K | 592,761 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Jan 12, 2026 | Sale | −10,000 | $28.34 | $283.40K | 144,846 |
| Sean Bohen President and CEO, Director | Dec 26, 2025 | Gift | −8,500 | – | – | 237,650 |
| Naseem Zojwalla Chief Medical Officer | Dec 23, 2025 | Option exercise | +50,000 | $7.02 | $351.00K | 103,997 |
| Naseem Zojwalla Chief Medical Officer | Dec 23, 2025 | Sale | −99,509 | $27.66 | $2.75M | 4,488 |
| Cyrus Harmon Director | Dec 22, 2025 | Sale | −2,881 | $28.53 | $82.19K | 741,259 |
| Naseem Zojwalla Chief Medical Officer | Dec 22, 2025 | Option exercise | +7,182 | $7.02 | $50.42K | 153,997 |
| Naseem Zojwalla Chief Medical Officer | Dec 22, 2025 | Option exercise | +42,818 | $15.25 | $652.97K | 146,815 |
| Naseem Zojwalla Chief Medical Officer | Dec 22, 2025 | Sale | −100,000 | $28.04 | $2.80M | 53,997 |
| Ian T. Clark Director | Dec 19, 2025 | Sale | −41,840 | $30.48 | $1.28M | 0 |
| Ian T. Clark Director | Dec 19, 2025 | Sale | −193,056 | $29.71 | $5.74M | 41,840 |
| Ian T. Clark Director | Dec 19, 2025 | Sale | −29,904 | $28.83 | $862.13K | 234,896 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +12,070 | $4.08 | $49.25K | 264,800 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +21,520 | $7.84 | $168.72K | 252,730 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +21,520 | $3.61 | $77.69K | 231,210 |
| Ian T. Clark Director | Dec 19, 2025 | Option exercise | +209,690 | $4.41 | $924.73K | 209,690 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sale | −1,225 | $28.08 | $34.40K | 601,656 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sale | −43,729 | $30.40 | $1.33M | 557,927 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sale | −6,046 | $31.39 | $189.78K | 551,881 |
| David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Gift | −9,000 | – | – | 542,881 |
| Naseem Zojwalla Chief Medical Officer | Dec 19, 2025 | Sale | −12,921 | $28.93 | $373.80K | 103,997 |
| Naseem Zojwalla Chief Medical Officer | Dec 19, 2025 | Sale | −57,079 | $28.03 | $1.60M | 116,918 |
| Naseem Zojwalla Chief Medical Officer | Dec 19, 2025 | Option exercise | +40,000 | $15.25 | $610.00K | 173,997 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Dec 8, 2025 | Gift | −75,000 | – | – | 243,549 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Nov 26, 2025 | Gift | −225,000 | – | – | 318,549 |
| Andrew Rappaport Director | Nov 25, 2025 | Gift | −35,868 | – | – | 0 |
| Andrew Rappaport Director | Nov 21, 2025 | Option exercise | +35,868 | $0.39 | $13.99K | 35,868 |
| Cyrus Harmon Director | Sep 18, 2025 | Sale | −3,086 | $8.32 | $25.68K | 117,028 |
| Cyrus Harmon Director | Sep 18, 2025 | Sale | −10,000 | $8.33 | $83.30K | 744,140 |
| Cyrus Harmon Director | Sep 16, 2025 | Sale | −1,914 | $8.08 | $15.47K | 120,114 |
| Cyrus Harmon Director | Sep 16, 2025 | Sale | −10,000 | $8.04 | $80.40K | 754,140 |
| Partners OS Ltd. BVF Director | Jan 10, 2025 | Returned to company | −22,740 | – | – | 347,970 |
| Partners OS Ltd. BVF Director | Jan 10, 2025 | Returned to company | −235,450 | – | – | 2,655,977 |
| Partners OS Ltd. BVF Director | Jan 10, 2025 | Returned to company | −161,810 | – | – | 2,003,966 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Jan 10, 2025 | Other | −3,500,000 | – | – | 4,300,000 |
| Bain Capital Life Sciences Investors, LLC 10% owner | Jan 8, 2025 | Buy | +300,000 | $5.76 | $1.73M | 7,800,000 |
| G. Walmsley Graham Director | Dec 17, 2024 | Sale | −700,761 | $6.75 | $4.73M | 0 |
| G. Walmsley Graham Director | Dec 17, 2024 | Buy | −700,761 | $6.75 | $4.73M | 1,408,875 |
| Naseem Zojwalla CHIEF MEDICAL OFFICER | Dec 16, 2024 | Option exercise | +14,000 | $4.87 | $68.18K | 129,509 |
| G. Walmsley Graham Director | Dec 13, 2024 | Buy | +700,761 | $6.75 | $4.73M | 700,761 |
| G. Walmsley Graham Director | Dec 13, 2024 | Sale | −700,761 | $6.75 | $4.73M | 0 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Dec 11, 2024 | Sale | −406 | $9.39 | $3.81K | 543,549 |
| Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | Dec 11, 2024 | Sale | −17,950 | $8.66 | $155.45K | 543,955 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Olema Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,913 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cyrus Harmon Director | Jul 24, 2026 | 12,500 | $146.42K | Jul 24, 2026 | Founders Shares |
| Cyrus Harmon Director | Jul 23, 2026 | 12,500 | $144.74K | Jul 23, 2026 | Founders Shares |
| Shane William Charles Kovacs Former Officer | Mar 16, 2026 | 100,000 | $1.61M | Mar 16, 2026 | Option Granted - 02/01/2023 |
| Shane William Charles Kovacs Former Officer | Mar 16, 2026 | 4,166 | $69.18K | Mar 16, 2026 | Option Granted - 02/01/2023 |
| Shane William Charles Kovacs Former Officer | Mar 11, 2026 | 50,000 | $796.80K | Mar 11, 2026 | Option Granted - 02/01/2023 |
| Shane William Charles Kovacs Former Officer | Mar 10, 2026 | 53,206 | $904.57K | Mar 10, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Mar 9, 2026 | 241,999 | $3.25M | Mar 9, 2026 | Option Granted 02/01/2022 |
| Shane William Charles Kovacs Former Officer | Mar 4, 2026 | 20,000 | $488.65K | Mar 4, 2026 | Restricted Stock Vesting |
| Shawnte Mitchell Officer | Mar 4, 2026 | 25,000 | $598.50K | Mar 4, 2026 | Option Granted - 02/28/2025 |
| Shawnte Mitchell Officer | Mar 3, 2026 | 15,000 | $345.15K | Mar 3, 2026 | Options Granted - 02/28/2025 |
| Shane William Charles Kovacs Former Officer | Feb 27, 2026 | 6,521 | $163.03K | Feb 27, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 24, 2026 | 20,000 | $500.00K | Feb 24, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 23, 2026 | 10,000 | $243.00K | Feb 23, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 23, 2026 | 20,000 | $480.01K | Feb 23, 2026 | Restricted Stock Vesting |
| Shane William Charles Kovacs Former Officer | Feb 12, 2026 | 10,000 | $238.50K | Feb 12, 2026 | Restricted Stock Vesting |
See a number that looks wrong?